Overview
- Japan’s health ministry cleared Sumitomo Pharma’s Amchepry for Parkinson’s disease and Cuorips’ ReHeart (RiHEART) for severe ischemic heart failure under time‑limited, conditional approvals.
- The pathway allows marketing based on smaller patient datasets than standard trials and requires continued monitoring and additional data collection after launch.
- Companies and officials say patient access could begin within months pending national pricing and public‑insurance decisions, with reports pointing to summer for initial availability and autumn for ReHeart sales.
- Amchepry transplants donor‑derived iPS cells matured into dopamine‑producing neuronal precursors into the brain, while ReHeart applies sheets of iPS‑derived cardiomyocytes to the heart to support blood‑vessel regeneration and function.
- A Kyoto University‑led study of the Parkinson’s approach followed seven patients for two years, reported no major adverse events, and saw symptom improvement in four participants, according to published reports.